Product Images Lojaimiess

This information appears to be related to a study or data analysis concerning menstrual cycles and bleeding or spotting. The text includes figures related to the duration of cycles, ranging from 27 days to 220 days, as well as percentages of women experiencing bleeding or spotting. Additionally, there are references to different cycles and the number of participants in each cycle. This data could potentially be used to analyze patterns or outcomes related to menstrual health.*

Levonorgestrel is a chemical compound with a molecular formula of C21H28O2 and a molecular weight of 312.4 g/mol. It is commonly used in birth control pills and emergency contraception.*

This is not readable.*

The text contains information about two types of tablets, Levonorgestrel and Ethinyl Estradiol, in different dosages of 0.1mg/0.02mg and 0.01mg. The tablets are packaged in extended-cycle blister packs. The first type has the NDC number 7070020733 and the second type has NDC number 7670020753. This information seems to pertain to pharmaceutical products.*

This text provides information about different methods of birth control and their effectiveness in preventing pregnancies. It lists various options, such as implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal rings with hormones, condoms, diaphragm, avoiding sex during fertile days, spermicide, withdrawal, and the concept of no birth control leading to pregnancies. It also categorizes the effectiveness of birth control methods based on the number of pregnancies per 100 women in one year.*

This text provides information on relevant studies evaluating the risk of breast cancer with combined oral contraceptives (COC). It includes comparisons of Ever COC vs. Never COC Use as well as Current COC use vs. Never-Use, showcasing data from studies such as the NICHD Women's Care Study, French E3N cohort Study, Shanghai Women's Health Study, The Nurses' Health Study, and the Oxford Family Planning Study among others. Different effect estimates such as Relative Risk (RR), Odds Ratio (OR), and Hazard Ratio (HR) are used to analyze the risk.*

This text provides information on the risk of developing a blood clot for various groups of women such as non-pregnant, non-COC (Combined Oral Contraceptive) users, COC users, pregnant women, and postpartum women. The data includes ranges of blood clot occurrences per 10,000 Women Years (WY) for each group. It also mentions that the pregnancy data is based on actual pregnancy duration, with a calculated rate of 7 to 27 blood clots per 10,000 WY.*